Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus
- Address
- Im Prüfling 17-19, 60389 Frankfurt, Germany
Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus
The Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus is a specialized hematology and oncology center dedicated to advancing cancer treatment through innovative clinical research. The center focuses particularly on breast cancer therapeutics and novel targeted therapies for patients with high-risk disease profiles.
- HER2-negative breast cancer treatment strategies
- Neoadjuvant therapy optimization and post-treatment management
- Antibody-drug conjugate therapies including sacituzumab govitecan
The center's research emphasizes improving outcomes for patients with high relapse risk following standard treatments, with a particular focus on evaluating invasive disease-free survival endpoints. Their work contributes to identifying optimal therapeutic approaches for challenging breast cancer subtypes that require specialized intervention strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparison of Adjuvant Elacestrant with Standard Endocrine Therapy in High-Risk ER+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 3 | Unknown | 2020-07-23 | 2022-04-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.